TLR4 agonists as vaccine adjuvants: a chemist’s perspective

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

This work was sponsored by GlaxoSmithKline Biologicals SA; unpublished data reported herein were supported in part by the National Institutes of Allergy and Infectious Diseases (NIAID) contract no. HHSN27200900008C. Any opinions, findings, and conclusions or recommendations expressed herein are those of the author and do not necessarily reflect the views of the NIAID. DA Johnson is an employee of GlaxoSmithKline Vaccines and owns shares and options to purchase shares in GlaxoSmithKline. DA Johnson is also a designated inventor on a pending patent application regarding TRIF-selective vaccine adjuvants. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Cervarix^™ and FENDrix^™ are trademarks of the GlaxoSmithKline group of companies.

No writing assistance was utilized in the production of this manuscript.